Read the full stored bill text
LEGISLATIVE BILL 877
Approved by the Governor March 3, 2026
Introduced by Hallstrom, 1.
A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to amend
section 28-405, Revised Statutes Supplement, 2025; to designate certain
substances as controlled substances; to correct the spelling of certain
substances; and to repeal the original section.
Be it enacted by the people of the State of Nebraska,
Section 1. Section 28-405, Revised Statutes Supplement, 2025, is amended
to read:
28-405 The following are the schedules of controlled substances referred
to in the Uniform Controlled Substances Act, unless specifically contained on
the list of exempted products of the Drug Enforcement Administration of the
United States Department of Justice as the list existed on January 31, 2022:
Schedule I
(a) Any of the following opiates, including their isomers, esters, ethers,
salts, and salts of isomers, esters, and ethers, unless specifically excepted,
whenever the existence of such isomers, esters, ethers, and salts is possible
within the specific chemical designation:
(1) Acetylmethadol;
(2) Allylprodine;
(3) Alphacetylmethadol, except levo-alphacetylmethadol which is also known
as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
(4) Alphameprodine;
(5) Alphamethadol;
(6) Benzethidine;
(7) Betacetylmethadol;
(8) Betameprodine;
(9) Betamethadol;
(10) Betaprodine;
(11) Clonitazene;
(12) Dextromoramide;
(13) Difenoxin;
(14) Diampromide;
(15) Diethylthiambutene;
(16) Dimenoxadol;
(17) Dimepheptanol;
(18) Dimethylthiambutene;
(19) Dioxaphetyl butyrate;
(20) Dipipanone;
(21) Ethylmethylthiambutene;
(22) Etonitazene;
(23) Etoxeridine;
(24) Furethidine;
(25) Hydroxypethidine;
(26) Ketobemidone;
(27) Levomoramide;
(28) Levophenacylmorphan;
(29) Morpheridine;
(30) Noracymethadol;
(31) Norlevorphanol;
(32) Normethadone;
(33) Norpipanone;
(34) Phenadoxone;
(35) Phenampromide;
(36) Phenomorphan;
(37) Phenoperidine;
(38) Piritramide;
(39) Proheptazine;
(40) Properidine;
(41) Propiram;
(42) Racemoramide;
(43) Trimeperidine;
(44) Alpha-methylfentanyl, N-(1-(alpha-methyl-beta-phenyl)ethyl-4-
piperidyl) propionanilide, 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)
piperidine;
(45) Tilidine;
(46) 3-Methylfentanyl, N-(3-methyl-1-(2-phenylethyl)-4-piperidyl)-N-
phenylpropanamide, its optical and geometric isomers, salts, and salts of
isomers;
(47) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP), its optical isomers,
salts, and salts of isomers;
(48) PEPAP, 1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine, its optical
isomers, salts, and salts of isomers;
(49) Acetyl-alpha-methylfentanyl, N-(1-(1-methyl-2-phenethyl)-4-
LB877
2026
LB877
2026
-1-
piperidinyl)-N-phenylacetamide, its optical isomers, salts, and salts of
isomers;
(50) Alpha-methylthiofentanyl, N-(1-methyl-2-(2-thienyl)ethyl-4-
piperidinyl)-N-phenylpropanamide, its optical isomers, salts, and salts of
isomers;
(51) Benzylfentanyl, N-(1-benzyl-4-piperidyl)-N-phenylpropanamide, its
optical isomers, salts, and salts of isomers;
(52) Beta-hydroxyfentanyl, N-(1-(2-hydroxy-2-phenethyl)-4-piperidinyl)-N-
phenylpropanamide, its optical isomers, salts, and salts of isomers;
(53) Beta-hydroxy-3-methylfentanyl, (other name: N-(1-(2-hydroxy-2-
phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide), its optical and
geometric isomers, salts, and salts of isomers;
(54) 3-methylthiofentanyl, N-(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl)-
N-phenylpropanamide, its optical and geometric isomers, salts, and salts of
isomers;
(55) N-(1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropanamide
(thenylfentanyl), its optical isomers, salts, and salts of isomers;
(56) Thiofentanyl, N-phenyl-N-(1-(2-thienyl)ethyl-4-piperidinyl)-
propanamide, its optical isomers, salts, and salts of isomers;
(57) Para-fluorofentanyl, N-(4-fluorophenyl)-N-(1-(2-phenethyl)-4-
piperidinyl)propanamide, its optical isomers, salts, and salts of isomers;
(58) U-47700, 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-
methylbenzamide;
(59) 4-Fluoroisobutyryl Fentanyl;
(60) Acetyl Fentanyl;
(61) Acyrloylfentanyl;
(62) AH-7921; 3, 4-dichloro-N-[(1-dimethylamino) cyclohexylmethyl]
benzamide;
(63) Butyryl fentanyl;
(64) Cyclopentyl fentanyl;
(65) Cyclopropyl fentanyl;
(66) Furanyl fentanyl;
(67) Isobutyryl fentanyl;
(68) Isotonitazene;
(69) Methoxyacetyl fentanyl;
(70) MT-45; 1-cyclohexyl-4-(1,2-diphenylethyl) piperazine;
(71) Tetrahydrofuranyl fentanyl;
(72) 2-fluorofentanyl; N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
propionamide;
(73) Ocfentanil;
(74) Ortho-Fluorofentanyl;
(75) Para-chloroisobutyryl fentanyl;
(76) Para-Fluorobutyryl Fentanyl;
(77) Valeryl fentanyl;
(78) Phenyl Fentanyl;
(79) Para-Methylfentanyl;
(80) Thiofuranyl Fentanyl;
(81) Beta-methyl Fentanyl;
(82) Beta'-Phenyl Fentanyl;
(83) Crotonyl Fentanyl;
(84) 2'-Fluoro Ortho-Fluorofentanyl;
(85) 4'-Methyl Acetyl Fentanyl;
(86) Ortho-Fluorobutyryl Fentanyl;
(87) Ortho-Methyl Acetylfentanyl;
(88) Ortho-Methyl Methoxyacetyl Fentanyl;
(89) Ortho-Fluoroacryl Fentanyl;
(90) Fentanyl Carbamate;
(91) Ortho-Fluoroisobutyryl Fentanyl;
(92) Para-Fluoro Furanyl Fentanyl;
(93) Para-Methoxybutyryl Fentanyl;
(94) Meta-Fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-
yl)propionamide);
(95) Meta-Fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)isobutyramide);
(96) Para-Methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-
phenethylpiperidin-4-yl)furan-2-carboxamide);
(97) 3-Furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-
carboxamide);
(98) 2',5'-Dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-
yl)-N-phenylpropionamide);
(99) Isovalerylfentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-
phenylbutanamide);
(100) Ortho-Fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)furan-2-carboxamide);
(101) Alpha-Methylbutyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-
yl)-N-phenylbutanamide);
(102) Para-methyl cyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-
phenethylpiperidin-4-yl)cyclopropanecarboxamide);
(103) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-
N,N-diethylethan-1-amine);
(104) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-
benzimidazol-1-yl)ethan-1-amine);
(105) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-
LB877
2026
LB877
2026
-2-
benzimidazol-1-yl)ethan-1-amine);
(106) Etodesnitazene (other names: 2-(2-(4-ethoxybenzyl)-1H-
benzimidazol-1-yl)-N,N-diethylethan-1-amine; and etazene);
(107) N-pyrrolidino etonitazene (other names: 2-(4-ethoxybenzyl)-5-
nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole; and etonitazepyne);
(108) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-
benzimidazol-1-yl)ethan-1-amine);
(109) 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one
(commonly known as 2-Methyl AP-237);
(110) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-
dihydro-2H-benzo[d]imidazol-2-one) (other name: 1-(1-(1-(4-bromophenyl) ethyl)
piperidin-4-yl-1,3-dihydro-2H-benzo[D]imidazole-2-one);
(111) Fentanyl-related substances, their isomers, esters, ethers, salts
and salts of isomers, esters, and ethers. Unless specifically excepted, listed
in another schedule, or specifically named in this schedule, this includes any
substance that is structurally related to fentanyl by one or more of the
following modifications:
(A) Replacement of the phenyl portion of the phenethyl group by any
monocycle, whether or not further substituted in or on the monocycle;
(B) Substitution in or on the phenethyl group with alkyl, alkenyl,
alkoxyl, hydroxyl, halo, haloalkyl, amino, or nitro groups;
(C) Substitution in or on the piperidine ring with alkyl, alkenyl,
alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino, or nitro groups;
(D) Replacement of the aniline ring with any aromatic monocycle whether or
not further substituted in or on the aromatic monocycle; or
(E) Replacement of the N-propionyl group by another acyl group; and
(112) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-
benzimidazol-1-yl)ethan-1-amine); .
(113) Para-chlorofentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-
yl)propionamide);
(114) Ortho-chlorofentanyl (N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-
yl)propionamide);
(115) Meta-fluorofuranyl fentanyl (N-(3-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)furan-2-carboxamide);
(116) Ortho-methylcyclopropyl fentanyl (N-(2-methylphenyl)-N-(1-
phenethylpiperidin-4-yl)cyclopropanecarboxamide);
(117) Beta-methylacetyl fentanyl (N-phenyl-N-(1-(2-
phenylpropyl)piperidin-4-yl)acetamide);
(118) Tetrahydrothiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-
phenyltetrahydrothiophene-2-carboxamide);
(119) Para-fluoro valeryl fentanyl (N-(4-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)pentanamide);
(120) Ethyleneoxynitazene (2-(2-((2,3-Dihydrobenzofuran-5-yl)methyl)-5-
nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine);
(121) Methylenedioxynitazene (other names: 2-(2-(Benzodioxol-5-
ylmethyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine and 3′,4′-
methylenedioxynitazene);
(122) 5-methyl etodesnitazene (2-(2-(4-ethoxybenzyl)-5-methyl-1H-
benzimidazol-1-yl)-N,N-diethylethan-1-amine);
(123) N-Desethyl protonitazene (N-ethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-
benzimidazol-1-yl)ethan-1-amine);
(124) N-desethyl etonitazene (2-(2-(4-Ethoxybenzyl)-5-nitro-1H-
benzimidazol-1-yl)-N-ethylethan-1-amine);
(125) N,N-Dimethylamino etonitazene (2-(2-(4-Ethoxybenzyl)-5-nitro-1H-
benzimidazol-1-yl)-N,N-dimethylethan-1-amine);
(126) N-desethyl isotonitazene (N-ethyl-2-(2-(4-isopropoxybenzyl)-5-
nitro-1H-benzimidazol-1-yl)ethan-1-amine);
(127) Metonitazepyne (other names: 2-(4-methoxybenzyl)-5-nitro-1-(2-
(pyrrolidin-1-yl)ethyl)-1H-benzimidazole and N-pyrrolidino metonitazene); and
(128) Protonitazepyne (other names: 5-nitro-2-(4-propoxybenzyl)-1-(2-
(pyrrolidin-1-yl)ethyl)-1H-benzimidazole and N-pyrrolidino protonitazene).
(b) Any of the following opium derivatives, their salts, isomers, and
salts of isomers, unless specifically excepted, whenever the existence of such
salts, isomers, and salts of isomers is possible within the specific chemical
designation:
(1) Acetorphine;
(2) Acetyldihydrocodeine;
(3) Benzylmorphine;
(4) Codeine methylbromide;
(5) Codeine-N-Oxide;
(6) Cyprenorphine;
(7) Desomorphine;
(8) Dihydromorphine;
(9) Drotebanol;
(10) Etorphine, except hydrochloride salt;
(11) Heroin;
(12) Hydromorphinol;
(13) Methyldesorphine;
(14) Methyldihydromorphine;
(15) Morphine methylbromide;
(16) Morphine methylsulfonate;
(17) Morphine-N-Oxide;
(18) Myrophine;
LB877
2026
LB877
2026
-3-
(19) Nicocodeine;
(20) Nicomorphine;
(21) Normorphine;
(22) Pholcodine; and
(23) Thebacon.
(c) Any material, compound, mixture, or preparation which contains any
quantity of the following hallucinogenic substances, their salts, isomers, and
salts of isomers, unless specifically excepted, whenever the existence of such
salts, isomers, and salts of isomers is possible within the specific chemical
designation, and, for purposes of this subdivision only, isomer shall include
the optical, position, and geometric isomers:
(1) Bufotenine. Trade and other names shall include, but are not limited
to: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-
indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; and mappine;
(2) 4-bromo-2,5-dimethoxyamphetamine. Trade and other names shall include,
but are not limited to: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; and
4-bromo-2,5-DMA;
(3) 4-methoxyamphetamine. Trade and other names shall include, but are not
limited to: 4-methoxy-alpha-methylphenethylamine; and paramethoxyamphetamine,
PMA;
(4) 4-methyl-2,5-dimethoxyamphetamine. Trade and other names shall
include, but are not limited to: 4-methyl-2,5-dimethoxy-alpha-
methylphenethylamine; DOM; and STP;
(5) Para-methoxymethamphetamine. Trade and other names shall include, but
are not limited to: 1-(4-Methoxyphenyl)-N-methylpropan-2-amine, PMMA, and 4-
MMA;
(6) Ibogaine. Trade and other names shall include, but are not limited to:
7-Ethyl-6,6beta,7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido
(1',2':1,2) azepino (5,4-b) indole; and Tabernanthe iboga;
(7) Lysergic acid diethylamide;
(8) Marijuana;
(9) Mescaline;
(10) Methoxetamine (MXE);
(11) Peyote. Peyote means all parts of the plant presently classified
botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds
thereof, any extract from any part of such plant, and every compound,
manufacture, salts, derivative, mixture, or preparation of such plant or its
seeds or extracts;
(12) Psilocybin. Psilocybin does not include any pharmaceutical
composition of crystalline polymorph psilocybin approved by the federal Food
and Drug Administration;
(13) Psilocin Psilocyn;
(14) Tetrahydrocannabinols, including, but not limited to, synthetic
equivalents of the substances contained in the plant or in the resinous
extractives of cannabis, sp. or synthetic substances, derivatives, and their
isomers with similar chemical structure and pharmacological activity such as
the following: Delta 1 cis or trans tetrahydrocannabinol and their optical
isomers, excluding dronabinol in a drug product approved by the federal Food
and Drug Administration; Delta 6 cis or trans tetrahydrocannabinol and their
optical isomers; and Delta 3,4 cis or trans tetrahydrocannabinol and its
optical isomers. Since nomenclature of these substances is not internationally
standardized, compounds of these structures shall be included regardless of the
numerical designation of atomic positions covered. Tetrahydrocannabinols does
not include cannabidiol contained in a drug product approved by the federal
Food and Drug Administration;
(15) N-ethyl-3-piperidyl benzilate;
(16) N-methyl-3-piperidyl benzilate;
(17) Thiophene analog of phencyclidine. Trade and other names shall
include, but are not limited to: 1-(1-(2-thienyl)-cyclohexyl)-piperidine; 2-
thienyl analog of phencyclidine; TPCP; and TCP;
(18) Hashish or concentrated cannabis;
(19) Parahexyl. Trade and other names shall include, but are not limited
to: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo(b,d)pyran;
and Synhexyl;
(20) Ethylamine analog of phencyclidine. Trade and other names shall
include, but are not limited to: N-ethyl-1-phenylcyclohexylamine; (1-
phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine;
and PCE;
(21) Pyrrolidine analog of phencyclidine. Trade and other names shall
include, but are not limited to: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; and
PHP;
(22) Alpha-ethyltryptamine. Some trade or other names: etryptamine;
Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl) indole; alpha-ET;
and AET;
(23) 2,5-dimethoxy-4-ethylamphet-amine; and DOET;
(24) 1-(1-(2-thienyl)cyclohexyl)pyrrolidine; and TCPy;
(25) Alpha-methyltryptamine, which is also known as AMT;
(26) Salvia divinorum or Salvinorin A. Salvia divinorum or Salvinorin A
includes all parts of the plant presently classified botanically as Salvia
divinorum, whether growing or not, the seeds thereof, any extract from any part
of such plant, and every compound, manufacture, derivative, mixture, or
preparation of such plant, its seeds, or its extracts, including salts,
isomers, and salts of isomers whenever the existence of such salts, isomers,
LB877
2026
LB877
2026
-4-
and salts of isomers is possible within the specific chemical designation;
(27) 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one (other names:
eutylone or bk-EBDB);
(28) Any material, compound, mixture, or preparation containing any
quantity of synthetically produced cannabinoids as listed in subdivisions (A)
through (L) of this subdivision, including their salts, isomers, salts of
isomers, and nitrogen, oxygen, or sulfur-heterocyclic analogs, unless
specifically excepted elsewhere in this section. Since nomenclature of these
synthetically produced cannabinoids is not internationally standardized and may
continually evolve, these structures or compounds of these structures shall be
included under this subdivision, regardless of their specific numerical
designation of atomic positions covered, so long as it can be determined
through a recognized method of scientific testing or analysis that the
substance contains properties that fit within one or more of the following
categories:
(A) Tetrahydrocannabinols: Meaning tetrahydrocannabinols naturally
contained in a plant of the genus cannabis (cannabis plant), as well as
synthetic equivalents of the substances contained in the plant, or in the
resinous extractives of cannabis, sp. and/or synthetic substances, derivatives,
and their isomers with similar chemical structure and pharmacological activity
such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their
optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical
isomers; Delta 3,4 cis or trans tetrahydrocannabinol, and its optical isomers.
This subdivision does not include cannabidiol contained in a drug product
approved by the federal Food and Drug Administration;
(B) Naphthoylindoles: Any compound containing a 3-(1-naphthoyl)indole
structure with substitution at the nitrogen atom of the indole ring by an
alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further
substituted in or on any of the listed ring systems to any extent;
(C) Naphthylmethylindoles: Any compound containing a 1 H-indol-3-yl-(1-
naphthyl)methane structure with substitution at the nitrogen atom of the indole
ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further
substituted in or on any of the listed ring systems to any extent;
(D) Naphthoylpyrroles: Any compound containing a 3-(1-naphthoyl)pyrrole
structure with substitution at the nitrogen atom of the pyrrole ring by an
alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further
substituted in or on any of the listed ring systems to any extent;
(E) Naphthylideneindenes: Any compound containing a naphthylideneindene
structure with substitution at the 3-position of the indene ring by an alkyl,
haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl,
2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, whether or not further substituted in or on any
of the listed ring systems to any extent;
(F) Phenylacetylindoles: Any compound containing a 3-phenylacetylindole
structure with substitution at the nitrogen atom of the indole ring by an
alkyl, haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-
piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-
morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further
substituted in or on any of the listed ring systems to any extent;
(G) Cyclohexylphenols: Any compound containing a 2-(3-
hydroxycyclohexyl)phenol structure with substitution at the 5-position of the
phenolic ring by an alkyl, haloalkyl, alkenyl, halobenzyl, benzyl,
cycloalkylmethyl, cycloalkylethyl, 2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-
(N-methyl-2-piperidinyl)methyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-
methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not
substituted in or on any of the listed ring systems to any extent;
(H) Benzoylindoles: Any compound containing a 3-(benzoyl)indole structure
with substitution at the nitrogen atom of the indole ring by an alkyl,
haloalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl,
2-(4-morpholinyl)ethyl group, cyanoalkyl, 1-(N-methyl-2-piperidinyl)methyl, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, whether or not further substituted in or on any
of the listed ring systems to any extent;
(I) Adamantoylindoles: Any compound containing a 3-adamantoylindole
structure with substitution at the nitrogen atom of the indole ring by an
alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, whether or not further substituted in or on any
of the listed ring systems to any extent;
(J) Tetramethylcyclopropanoylindoles: Any compound containing a 3-
tetramethylcyclopropanoylindole structure with substitution at the nitrogen
LB877
2026
LB877
2026
-5-
atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl,
halobenzyl, benzyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-
piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl,
1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or
not further substituted in or on any of the listed ring systems to any extent;
(K) Indole carboxamides: Any compound containing a 1-indole-3-carboxamide
structure with substitution at the nitrogen atom of the indole ring by an
alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, substitution at the carboxamide group by an
alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl,
aminooxoalkyl group, or quinolinyl group, whether or not further substituted in
or on any of the listed ring systems to any extent or to the adamantyl, 1-
mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any
extent;
(L) Indole carboxylates: Any compound containing a 1-indole-3-carboxylate
structure with substitution at the nitrogen atom of the indole ring by an
alkyl, haloalkyl, cyanoalkyl, alkenyl, halobenzyl, benzyl, cycloalkylmethyl,
cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-
(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or
tetrahydropyranylmethyl group, substitution at the carboxylate group by an
alkyl, methoxy, benzyl, propionaldehyde, adamantyl, 1-naphthyl, phenyl,
aminooxoalkyl group, or quinolinyl group, whether or not further substituted in
or on any of the listed ring systems to any extent or to the adamantyl, 1-
mapthyl, phenyl, aminooxoalkyl, benzyl, or propionaldehyde groups to any
extent; and
(M) Any nonnaturally occurring substance, chemical compound, mixture, or
preparation, not specifically listed elsewhere in these schedules and which is
not approved for human consumption by the federal Food and Drug Administration,
containing or constituting a cannabinoid receptor agonist as defined in section
28-401;
(29) Zipeprol 1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-
phenylpropan-2-ol, including its isomers, esters, ethers, salts, and salts of
isomers, esters, and ethers, whenever the existence of such isomers, esters,
ethers, and salts is possible within the specific chemical designation;
(30) Any material, compound, mixture, or preparation containing any
quantity of a substituted phenethylamine as listed in subdivisions (A) through
(C) of this subdivision, unless specifically excepted, listed in another
schedule, or specifically named in this schedule, that is structurally derived
from phenylethan-2-amine by substitution on the phenyl ring with a fused
methylenedioxy ring, fused furan ring, or a fused tetrahydrofuran ring; by
substitution with two alkoxy groups; by substitution with one alkoxy and either
one fused furan, tetrahydrofuran, or tetrahydropyran ring system; or by
substitution with two fused ring systems from any combination of the furan,
tetrahydrofuran, or tetrahydropyran ring systems, whether or not the compound
is further modified in any of the following ways:
(A) Substitution of the phenyl ring by any halo, hydroxyl, alkyl,
trifluoromethyl, alkoxy, or alkylthio groups; (B) substitution at the 2-
position by any alkyl groups; or (C) substitution at the 2-amino nitrogen atom
with alkyl, dialkyl, benzyl, hydroxybenzyl, or methoxybenzyl groups, and
including, but not limited to:
(i) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C-
C or 2,5-Dimethoxy-4-chlorophenethylamine;
(ii) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine, which is also known as
2C-D or 2,5-Dimethoxy-4-methylphenethylamine;
(iii) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine, which is also known as
2C-E or 2,5-Dimethoxy-4-ethylphenethylamine;
(iv) 2-(2,5-Dimethoxyphenyl)ethanamine, which is also known as 2C-H or
2,5-Dimethoxyphenethylamine;
(v) 2-(4-lodo-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C-I
or 2,5-Dimethoxy-4-iodophenethylamine;
(vi) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine, which is also known as
2C-N or 2,5-Dimethoxy-4-nitrophenethylamine;
(vii) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine, which is also known
as 2C-P or 2,5-Dimethoxy-4-propylphenethylamine;
(viii) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine, which is also
known as 2C-T-2 or 2,5-Dimethoxy-4-ethylthiophenethylamine;
(ix) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine, which is also
known as 2C-T-4 or 2,5-Dimethoxy-4-isopropylthiophenethylamine;
(x) 2-(4-bromo-2,5-dimethoxyphenyl)ethanamine, which is also known as 2C-B
or 2,5-Dimethoxy-4-bromophenethylamine;
(xi) 2-(2,5-dimethoxy-4-(methylthio)phenyl)ethanamine, which is also known
as 2C-T or 4-methylthio-2,5-dimethoxyphenethylamine;
(xii) 1-(2,5-dimethoxy-4-iodophenyl)-propan-2-amine, which is also known
as DOI or 2,5-Dimethoxy-4-iodoamphetamine;
(xiii) 1-(4-Bromo-2,5-dimethoxyphenyl)-2-aminopropane, which is also known
as DOB or 2,5-Dimethoxy-4-bromoamphetamine;
(xiv) 1-(4-chloro-2,5-dimethoxy-phenyl)propan-2-amine, which is also known
as DOC or 2,5-Dimethoxy-4-chloroamphetamine;
(xv) 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine, which is also known as 2C-B-NBOMe; 25B-NBOMe
or 2,5-Dimethoxy-4-bromo-N-(2-methoxybenzyl)phenethylamine;
LB877
2026
LB877
2026
-6-
(xvi) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine, which is also known as 2C-I-NBOMe; 25I-NBOMe
or 2,5-Dimethoxy-4-iodo-N-(2-methoxybenzyl)phenethylamine;
(xvii) N-(2-Methoxybenzyl)-2-(3,4,5-trimethoxyphenyl)ethanamine, which is
also known as Mescaline-NBOMe or 3,4,5-trimethoxy-N-(2-
methoxybenzyl)phenethylamine;
(xviii) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-
methoxyphenyl)methyl]ethanamine, which is also known as 2C-C-NBOMe; or 25C-
NBOMe or 2,5-Dimethoxy-4-chloro-N-(2-methoxybenzyl)phenethylamine;
(xix) 2-(7-Bromo-5-methoxy-2,3-dihydro-1-benzofuran-4-yl)ethanamine, which
is also known as 2CB-5-hemiFLY;
(xx) 2-(8-bromo-2,3,6,7-tetrahydrofuro [2,3-f][1]benzofuran-4-
yl)ethanamine, which is also known as 2C-B-FLY;
(xxi) 2-(10-Bromo-2,3,4,7,8,9-hexahydropyrano[2,3-g]chromen-5-
yl)ethanamine, which is also known as 2C-B-butterFLY;
(xxii) N-(2-Methoxybenzyl)-1-(8-bromo-2,3,6,7- tetrahydrobenzo[1,2-b:4,5-
b']difuran-4-yl)-2-aminoethane, which is also known as 2C-B-FLY-NBOMe;
(xxiii) 1-(4-Bromofuro[2,3-f][1]benzofuran-8-yl)propan-2-amine, which is
also known as bromo-benzodifuranylisopropylamine or bromo-dragonFLY;
(xxiv) N-(2-Hydroxybenzyl)-4-iodo-2,5-dimethoxyphenethylamine, which is
also known as 2C-INBOH or 25I-NBOH;
(xxv) 5-(2-Aminopropyl)benzofuran, which is also known as 5-APB;
(xxvi) 6-(2-Aminopropyl)benzofuran, which is also known as 6-APB;
(xxvii) 5-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known as 5-
APDB;
(xxviii) 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, which is also known as
6-APDB;
(xxix) 2,5-dimethoxy-amphetamine, which is also known as 2,5-dimethoxy-a-
methylphenethylamine 2, 5-dimethoxy-a-methylphenethylamine; 2,5-DMA 2, 5-DMA;
(xxx) 2,5-dimethoxy-4-ethylamphetamine, which is also known as DOET;
(xxxi) 2,5-dimethoxy-4-(n)-propylthiophenethylamine, which is also known
as 2C-T-7;
(xxxii) 5-methoxy-3,4-methylenedioxy-amphetamine;
(xxxiii) 4-methyl-2,5-dimethoxy-amphetamine, which is also known as 4-
methyl-2,5-dimethoxy-amethylphenethylamine; DOM and STP;
(xxxiv) 3,4-methylenedioxy amphetamine, which is also known as MDA;
(xxxv) 3,4-methylenedioxymethamphetamine, which is also known as MDMA;
(xxxvi) 3,4-methylenedioxy-N-ethylamphetamine, which is also known as N-
ethyl-alpha-methyl-3,4(methylenedioxy)phenethylamine, MDE, MDEA;
(xxxvii) 3,4,5-trimethoxy amphetamine; and
(xxxviii) n-hydroxy-3, 4-Methylenedioxy-N-Hydroxyamphetamine, which is
also known as N-hydroxyMDA;
(31) Any material, compound, mixture, or preparation containing any
quantity of a substituted tryptamine unless specifically excepted, listed in
another schedule, or specifically named in this schedule, that is structurally
derived from 2-(1H-indol-3-yl)ethanamine, which is also known as tryptamine, by
mono- or di-substitution of the amine nitrogen with alkyl or alkenyl groups or
by inclusion of the amino nitrogen atom in a cyclic structure whether or not
the compound is further substituted at the alpha position with an alkyl group
or whether or not further substituted on the indole ring to any extent with any
alkyl, alkoxy, halo, hydroxyl, or acetoxy groups, and including, but not
limited to:
(A) 5-methoxy-N,N-diallyltryptamine, which is also known as 5-MeO-DALT;
(B) 4-acetoxy-N,N-dimethyltryptamine, which is also known as 4-AcO-DMT or
OAcetylpsilocin;
(C) 4-hydroxy-N-methyl-N-ethyltryptamine, which is also known as 4-HO-MET;
(D) 4-hydroxy-N,N-diisopropyltryptamine, which is also known as 4-HO-DIPT;
(E) 5-methoxy-N-methyl-N-isopropyltryptamine, which is also known as 5-
MeOMiPT;
(F) 5-Methoxy-N,N-Dimethyltryptamine, which is also known as 5-MeO-DMT;
(G) 5-methoxy-N,N-diisopropyltryptamine, which is also known as 5-MeO-
DiPT;
(H) Diethyltryptamine, which is also known as N,N-Diethyltryptamine, DET;
and
(I) Dimethyltryptamine, which is also known as DMT; and
(32)(A) Any substance containing any quantity of the following materials,
compounds, mixtures, or structures:
(i) 3,4-methylenedioxymethcathinone, or bk-MDMA, or methylone;
(ii) 3,4-methylenedioxypyrovalerone, or MDPV;
(iii) 4-methylmethcathinone, or 4-MMC, or mephedrone;
(iv) 4-methoxymethcathinone, or bk-PMMA, or PMMC, or methedrone;
(v) Fluoromethcathinone, or FMC;
(vi) Naphthylpyrovalerone, or naphyrone; or
(vii) Beta-keto-N-methylbenzodioxolylpropylamine or bk-MBDB or butylone;
or
(B) Unless listed in another schedule, any substance which contains any
quantity of any material, compound, mixture, or structure, other than
bupropion, that is structurally derived by any means from 2-aminopropan-1-one
by substitution at the 1-position with either phenyl, naphthyl, or thiophene
ring systems, whether or not the compound is further modified in any of the
following ways:
(i) Substitution in the ring system to any extent with alkyl, alkoxy,
alkylenedioxy, haloalkyl, hydroxyl, or halide substituents, whether or not
LB877
2026
LB877
2026
-7-
further substituted in the ring system by one or more other univalent
substituents;
(ii) Substitution at the 3-position with an acyclic alkyl substituent; or
(iii) Substitution at the 2-amino nitrogen atom with alkyl or dialkyl
groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure.
(d) Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a depressant effect on the central nervous system,
including its salts, isomers, and salts of isomers whenever the existence of
such salts, isomers, and salts of isomers is possible within the specific
chemical designation:
(1) Amineptine 7-[(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-
yl)amino]heptanoic acid, including its salts, isomers, and salts of isomers;
(2) Mecloqualone;
(3) Methaqualone; and
(4) Gamma-Hydroxybutyric Acid. Some other names include: GHB; Gamma-
hydroxybutyrate; 4-Hydroxybutyrate; 4-Hydroxybutanoic Acid; Sodium Oxybate; and
Sodium Oxybutyrate;
(5) Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4H-benzo[f]
[1,2,4]triazolo[4,3-a][1,4]diazepine); .
(6) Diclazepam (7-chloro-5-(2-chlorophenyl)-1,3-dihydro-1-methyl-2H-1,4-
benzodiazepin-2-one);
(7) Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f]
[1,2,4]triazolo[4,3-a][1,4]diazepine);
(8) Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4H-benzo[f]
[1,2,4]triazolo[4,3-a][1,4]diazepine); and
(9) Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methyl-4H-benzo[f]
[1,2,4]triazolo[4,3-a][1,4]diazepine).
(e) Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including its salts, isomers, and salts of isomers:
(1) Fenethylline;
(2) N-ethylamphetamine;
(3) Aminorex; aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5-dihydro-5-
phenyl-2-oxazolamine;
(4) Cathinone; 2-amino-1-phenyl-1-propanone; alpha-aminopropiophenone; 2-
aminopropiophenone; and norephedrone;
(5) Methcathinone, its salts, optical isomers, and salts of optical
isomers. Some other names: 2-(methylamino)-propiophenone; alpha-
(methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N-
methylaminopropiophenone; methylcathinone; monomethylpropion; ephedrone; N-
methylcathinone; AL-464; AL-422; AL-463; UR1432; and 4-MEC;
(6) (+/-)cis-4-methylaminorex; and (+/-)cis-4,5-dihydro-4-methyl-5-
phenyl-2-oxazolamine;
(7) N,N-dimethylamphetamine; N,N-alpha-trimethyl-benzeneethanamine; and
N,N-alpha-trimethylphenethylamine;
(8) Benzylpiperazine, 1-benzylpiperazine;
(9) 4,4'-dimethylaminorex (other names: 4,4'-DMAR, 4,5-dihydro-4-
methyl-5-(4-methylphenyl)-2-oxazolamine);
(10) N-phenyl-N' -(3-(1- phenylpropan-2-yl)-1,2,3-oxadiazol-3- ium-5-
yl)carbamimidate), including its salts, isomers, and salts of isomers;
(11) Mesocarb (N-phenyl-N'-(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-
ium-5-yl)carbamimidate); and
(12) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine); .
(13) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate); and
(14) Dipentylone (1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)pentan-1-one;
N,N-dimethylpentylone).
(f) Any controlled substance analogue to the extent intended for human
consumption.
Schedule II
(a) Any of the following substances except those narcotic drugs listed in
other schedules whether produced directly or indirectly by extraction from
substances of vegetable origin, independently by means of chemical synthesis,
or by combination of extraction and chemical synthesis:
(1) Opium and opiate, and any salt, compound, derivative, or preparation
of opium or opiate, excluding apomorphine, buprenorphine, thebaine-derived
butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone and
their salts, but including the following:
(A) Raw opium;
(B) Opium extracts;
(C) Opium fluid;
(D) Powdered opium;
(E) Granulated opium;
(F) Tincture of opium;
(G) Codeine;
(H) Ethylmorphine;
(I) Etorphine hydrochloride;
(J) Hydrocodone;
(K) Hydromorphone;
(L) Metopon;
(M) Morphine;
(N) Oxycodone;
LB877
2026
LB877
2026
-8-
(O) Oxymorphone;
(P) Oripavine;
(Q) Thebaine; and
(R) Dihydroetorphine;
(2) Any salt, compound, derivative, or preparation thereof which is
chemically equivalent to or identical with any of the substances referred to in
subdivision (1) of this subdivision, except that these substances shall not
include the isoquinoline alkaloids of opium;
(3) Opium poppy and poppy straw;
(4) Coca leaves and any salt, compound, derivative, or preparation of coca
leaves, and any salt, compound, derivative, or preparation thereof which is
chemically equivalent to or identical with any of these substances, including
cocaine or ecgonine and its salts, optical isomers, and salts of optical
isomers, except that the substances shall not include decocainized coca leaves
or extractions which do not contain cocaine or ecgonine; and
(5) Concentrate of poppy straw, the crude extract of poppy straw in either
liquid, solid, or powder form which contains the phenanthrene alkaloids of the
opium poppy.
(b) Unless specifically excepted or unless in another schedule any of the
following opiates, including their isomers, esters, ethers, salts, and salts of
their isomers, esters, and ethers whenever the existence of such isomers,
esters, ethers, and salts is possible within the specific chemical designation,
dextrorphan excepted:
(1) Alphaprodine;
(2) Anileridine;
(3) Bezitramide;
(4) Diphenoxylate;
(5) Fentanyl;
(6) Isomethadone;
(7) Levomethorphan;
(8) Levorphanol;
(9) Metazocine;
(10) Methadone;
(11) Methadone-intermediate, 4-cyano-2-dimethylamino-4,4-diphenyl butane;
(12) Moramide-intermediate, 2-methyl-3-morpholino-1,1-diphenylpropane-
carboxylic acid;
(13) Norfentanyl (N-phenyl-N-piperidin-4-yl) propionamide;
(14) Oliceridine;
(15) Pethidine or meperidine;
(16) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
(17) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(18) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic
acid;
(19) Phenazocine;
(20) Piminodine;
(21) Racemethorphan;
(22) Racemorphan;
(23) Dihydrocodeine;
(24) Bulk Propoxyphene in nondosage forms;
(25) Sufentanil;
(26) Alfentanil;
(27) Levo-alphacetylmethadol which is also known as levo-alpha-
acetylmethadol, levomethadyl acetate, and LAAM;
(28) Carfentanil;
(29) Remifentanil;
(30) Tapentadol; and
(31) Thiafentanil.
(c) Any material, compound, mixture, or preparation which contains any
quantity of the following substances having a potential for abuse associated
with a stimulant effect on the central nervous system:
(1) Amphetamine, its salts, optical isomers, and salts of its optical
isomers;
(2) Phenmetrazine and its salts;
(3) Methamphetamine, its salts, isomers, and salts of its isomers;
(4) Methylphenidate; and
(5) Lisdexamfetamine, its salts, isomers, and salts of its isomers.
(d) Any material, compound, mixture, or preparation which contains any
quantity of the following substances having a potential for abuse associated
with a depressant effect on the central nervous system, including their salts,
isomers, and salts of isomers whenever the existence of such salts, isomers,
and salts of isomers is possible within the specific chemical designations:
(1) Amobarbital;
(2) Secobarbital;
(3) Pentobarbital;
(4) Phencyclidine; and
(5) Glutethimide.
(e) Hallucinogenic substances known as:
(1) Nabilone. Another name for nabilone: (+/-)-trans-3-(1,1-
dimethylheptyl)- 6,6a,7,8,10,10a-Hexahydro-1-hydroxy-6,6-dimethyl-9H-
dibenzo(b,d)pyran-9-one; and
(2) Dronabinol in an oral solution in a drug product approved by the
federal Food and Drug Administration.
(f) Unless specifically excepted or unless listed in another schedule, any
LB877
2026
LB877
2026
-9-
material, compound, mixture, or preparation which contains any quantity of the
following substances:
(1) Immediate precursor to amphetamine and methamphetamine: Phenylacetone.
Trade and other names shall include, but are not limited to: Phenyl-2-
propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone;
(2) Immediate precursors to phencyclidine, PCP:
(A) 1-phenylcyclohexylamine; or
(B) 1-piperidinocyclohexanecarbonitrile, PCC;
(3) Immediate precursor to fentanyl; 4-anilino-N-phenethylpiperidine
(ANPP); or
(4) Tianeptine, its salts, isomers, and salts of isomers whenever the
existence of such salts, isomers, and salts of isomers is possible within the
specific chemical designation.
Schedule III
(a) Any material, compound, mixture, or preparation which contains any
quantity of the following substances having a potential for abuse associated
with a stimulant effect on the central nervous system, including their salts,
isomers, whether optical, position, or geometric, and salts of such isomers
whenever the existence of such salts, isomers, and salts of isomers is possible
within the specific chemical designation:
(1) Benzphetamine;
(2) Chlorphentermine;
(3) Clortermine; and
(4) Phendimetrazine.
(b) Any material, compound, mixture, or preparation which contains any
quantity of the following substances having a potential for abuse associated
with a depressant effect on the central nervous system:
(1) Any substance which contains any quantity of a derivative of
barbituric acid or any salt of a derivative of barbituric acid, except those
substances which are specifically listed in other schedules of this section;
(2) Aprobarbital;
(3) Butabarbital;
(4) Butalbital;
(5) Butethal;
(6) Butobarbital;
(7) Chlorhexadol;
(8) Embutramide;
(9) Lysergic acid;
(10) Lysergic acid amide;
(11) Methyprylon;
(12) Perampanel;
(13) Secbutabarbital;
(14) Sulfondiethylmethane;
(15) Sulfonethylmethane;
(16) Sulfonmethane;
(17) Nalorphine;
(18) Talbutal;
(19) Thiamylal;
(20) Thiopental;
(21) Vinbarbital;
(22) Any compound, mixture, or preparation containing amobarbital,
secobarbital, pentobarbital, or any salt thereof and one or more other active
medicinal ingredients which are not listed in any schedule;
(23) Any suppository dosage form containing amobarbital, secobarbital,
pentobarbital, or any salt of any of these drugs and approved by the federal
Food and Drug Administration for marketing only as a suppository;
(24) Any drug product containing gamma-hydroxybutyric acid, including its
salts, isomers, and salts of isomers, for which an application is approved
under section 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. 355,
as such section existed on January 1, 2014;
(25) Ketamine, its salts, isomers, and salts of isomers. Some other names
for ketamine: (+/-)-2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone;
(26) Tiletamine and zolazepam or any salt thereof. Trade or other names
for a tiletamine-zolazepam combination product shall include, but are not
limited to: telazol. Trade or other names for tiletamine shall include, but are
not limited to: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone. Trade or other
names for zolazepam shall include, but are not limited to: 4-(2-
fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-(3,4-e) (1,4)-diazepin-7(1H)-
one, and flupyrazapon; and
(27)(A) Xylazine or any of the substances listed below, including their
salts, isomers, and salts of isomers whenever the existence of such salts,
isomers, and salts of isomers is possible within the specific chemical
designation:
(i) Xylazine-M (2,6Mich dimethylaniline);
(ii) Xylazine-M (N-thiourea-2,6-dimethylaniline);
(iii) Xylazine-M (sulfone-HO-) isomer 2;
(iv) Xylazine-M (HO-2,6-dimethylaniline isomer 1);
(v) Xylazine-M (HO-2,6-dimethylaniline isomer 2);
(vi) Xylazine-M (oxo-);
(vii) Xylazine-M (HO-) isomer 1;
(viii) Xylazine-M (HO-) isomer 1 glucuronide;
(ix) Xylazine-M (HO-) isomer 2;
(x) Xylazine-M (HO-) isomer 2 glucuronide;
LB877
2026
LB877
2026
-10-
(xi) Xylazine-M (HO-oxo-) isomer 1;
(xii) Xylazine-M (HO-oxo-) isomer 1 glucuronide;
(xiii) Xylazine-M (HO-oxo-) isomer 2;
(xiv) Xylazine-M (HO-oxo-) isomer 2 glucuronide;
(xv) Xylazine-M (sulfone); and
(xvi) Xylazine-M (sulfone-HO-) isomer 1.
(B) This subdivision (27) shall not include xylazine when it is used in
any of the following manners:
(i) Dispensing or prescribing for, or administering to, a nonhuman species
a drug containing xylazine that has been approved by the United States
Secretary of Health and Human Services under section 512 of the Federal Food,
Drug, and Cosmetic Act, 21 U.S.C. 360b, as such act existed on January 1, 2025;
(ii) Dispensing or prescribing for, or administering to, a nonhuman
species that is permissible under section 512(a)(4) of the Federal Food, Drug,
and Cosmetic Act, 21 U.S.C. 360b(a)(4), as such act existed on January 1, 2025;
(iii) The manufacturing, distribution, or use of xylazine as an active
pharmaceutical ingredient for manufacturing an animal drug that has been
approved under section 512 of the Federal Food, Drug, and Cosmetic Act, 21
U.S.C. 360b, or that has been issued an investigational use exemption under
section 512(j) of the act, 21 U.S.C. 360b(j), as such act existed on January 1,
2025;
(iv) The manufacturing, distribution, or use of a xylazine bulk chemical
for pharmaceutical compounding by licensed pharmacists or veterinarians for a
nonhuman species in accordance with subdivision (B)(i) or (ii) of this
subdivision (27); or
(v) Any other use approved or permissible under the Federal Food, Drug,
and Cosmetic Act, when dispensed or prescribed for, or administered to, a
nonhuman species in accordance with subdivision (B)(i) or (ii) of this
subdivision (27).
(c) Unless specifically excepted or unless listed in another schedule:
(1) Any material, compound, mixture, or preparation containing limited
quantities of any of the following narcotic drugs, or any salts calculated as
the free anhydrous base or alkaloid, in limited quantities as set forth below:
(A) Not more than one and eight-tenths grams of codeine per one hundred
milliliters or not more than ninety milligrams per dosage unit, with an equal
or greater quantity of an isoquinoline alkaloid of opium;
(B) Not more than one and eight-tenths grams of codeine per one hundred
milliliters or not more than ninety milligrams per dosage unit, with one or
more active, nonnarcotic ingredients in recognized therapeutic amounts;
(C) Not more than one and eight-tenths grams of dihydrocodeine per one
hundred milliliters or not more than ninety milligrams per dosage unit, with
one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(D) Not more than three hundred milligrams of ethylmorphine per one
hundred milliliters or not more than fifteen milligrams per dosage unit, with
one or more active, nonnarcotic ingredients in recognized therapeutic amounts;
(E) Not more than five hundred milligrams of opium per one hundred
milliliters or per one hundred grams, or not more than twenty-five milligrams
per dosage unit, with one or more active, nonnarcotic ingredients in recognized
therapeutic amounts; and
(F) Not more than fifty milligrams of morphine per one hundred milliliters
or per one hundred grams with one or more active, nonnarcotic ingredients in
recognized therapeutic amounts; and
(2) Any material, compound, mixture, or preparation containing any of the
following narcotic drug or its salts, as set forth below:
(A) Buprenorphine.
(d) Unless contained on the list of exempt anabolic steroids of the Drug
Enforcement Administration of the United States Department of Justice as the
list existed on January 31, 2022, any anabolic steroid, which shall include any
material, compound, mixture, or preparation containing any quantity of the
following substances, including its salts, isomers, and salts of isomers
whenever the existence of such salts of isomers is possible within the specific
chemical designation:
(1) 3-beta,17-dihydroxy-5a-androstane;
(2) 3-alpha,17-beta-dihydroxy-5a-androstane;
(3) 5-alpha-androstan-3,17-dione;
(4) 1-androstenediol (3-beta,17-beta-dihydroxy-5-alpha-androst-1-ene);
(5) 1-androstenediol (3-alpha,17-beta-dihydroxy-5-alpha-androst-1-ene);
(6) 4-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
(7) 5-androstenediol (3-beta,17-beta-dihydroxy-androst-5-ene);
(8) 1-androstenedione ([5-alpha]-androst-1-en-3,17-dione);
(9) 4-androstenedione (androst-4-en-3,17-dione);
(10) 5-androstenedione (androst-5-en-3,17-dione);
(11) Bolasterone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3-
one);
(12) Boldenone (17-beta-hydroxyandrost-1,4-diene-3-one);
(13) Boldione (androsta-1,4-diene-3,17-3-one);
(14) Calusterone (7-beta,17-alpha-dimethyl-17-beta-hydroxyandrost-4-en-3-
one);
(15) Clostebol (4-chloro-17-beta-hydroxyandrost-4-en-3-one);
(16) Dehydrochloromethyltestosterone (4-chloro-17-beta-hydroxy-17-alpha-
methyl-androst-1,4-dien-3-one);
(17) Desoxymethyltestosterone (17-alpha-methyl-5-alpha-androst-2-en-17-
beta-ol) (a.k.a. 'madol');
LB877
2026
LB877
2026
-11-
(18) Delta-1-Dihydrotestosterone (a.k.a. '1-testosterone')(17-beta-
hydroxy-5-alpha-androst-1-en-3-one);
(19) 4-Dihydrotestosterone (17-beta-hydroxy-androstan-3-one);
(20) Drostanolone (17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-
one);
(21) Ethylestrenol (17-alpha-ethyl-17-beta-hydroxyestr-4-ene);
(22) Fluoxymesterone (9-fluoro-17-alpha-methyl-11-beta,17-beta-
dihydroxyandrost-4-en-3-one);
(23) Formebulone (formebolone); (2-formyl-17-alpha-methyl-11-alpha,17-
beta-dihydroxyandrost-1,4-dien-3-one);
(24) Furazabol (17-alpha-methyl-17-beta-hydroxyandrostano[2,3-c]-furazan);
(25) 13-beta-ethyl-17-beta-hydroxygon-4-en-3-one;
(26) 4-hydroxytestosterone (4,17-beta-dihydroxy-androst-4-en-3-one);
(27) 4-hydroxy-19-nortestosterone (4,17-beta-dihydroxy-estr-4-en-3-one);
(28) Mestanolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one);
(29) Mesterolone (17-alpha-methyl-17-beta-hydroxy-5-androstan-3-one);
(30) Methandienone (17-alpha-methyl-17-beta-hydroxyandrost-1,4-dien-3-
one);
(31) Methandriol (17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-5-ene);
(32) Methasterone (2-alpha,17-alpha-dimethyl-5-alpha-androstan-17-beta-
ol-3-one);
(33) Methenolone (1-methyl-17-beta-hydroxy-5-alpha-androst-1-en-3-one);
(34) 17-alpha-methyl-3-beta,17-beta-dihydroxy-5a-androstane;
(35) 17-alpha-methyl-3-alpha,17-beta-dihydroxy-5a-androstane;
(36) 17-alpha-methyl-3-beta,17-beta-dihydroxyandrost-4-ene;
(37) 17-alpha-methyl-4-hydroxynandrolone (17-alpha-methyl-4-hydroxy-17-
beta-hydroxyestr-4-en-3-one);
(38) Methyldienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9(10)-dien-3-
one);
(39) Methyltrienolone (17-alpha-methyl-17-beta-hydroxyestra-4,9,11-
trien-3-one);
(40) Methyltestosterone (17-alpha-methyl-17-beta-hydroxyandrost-4-en-3-
one);
(41) Mibolerone (7-alpha,17-alpha-dimethyl-17-beta-hydroxyestr-4-en-3-
one);
(42) 17-alpha-methyl-delta-1-dihydrotestosterone (17-beta-hydroxy-17-
alpha-methyl-5-alpha-androst-1-en-3-one) (a.k.a. '17-alpha-methyl-1-
testosterone');
(43) Nandrolone (17-beta-hydroxyestr-4-en-3-one);
(44) 19-nor-4-androstenediol (3-beta, 17-beta-dihydroxyestr-4-ene);
(45) 19-nor-4-androstenediol (3-alpha, 17-beta-dihydroxyestr-4-ene);
(46) 19-nor-5-androstenediol (3-beta, 17-beta-dihydroxyestr-5-ene);
(47) 19-nor-5-androstenediol (3-alpha, 17-beta-dihydroxyestr-5-ene);
(48) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione);
(49) 19-nor-4-androstenedione (estr-4-en-3,17-dione);
(50) 19-nor-5-androstenedione (estr-5-en-3,17-dione);
(51) Norbolethone (13-beta, 17-alpha-diethyl-17-beta-hydroxygon-4-en-3-
one);
(52) Norclostebol (4-chloro-17-beta-hydroxyestr-4-en-3-one);
(53) Norethandrolone (17-alpha-ethyl-17-beta-hydroxyestr-4-en-3-one);
(54) Normethandrolone (17-alpha-methyl-17-beta-hydroxyestr-4-en-3-one);
(55) Oxandrolone (17-alpha-methyl-17-beta-hydroxy-2-oxa-[5-alpha]-
androstan-3-one);
(56) Oxymesterone (17-alpha-methyl-4,17-beta-dihydroxyandrost-4-en-3-one);
(57) Oxymetholone (17-alpha-methyl-2-hydroxymethylene-17-beta-hydroxy-[5-
alpha]-androstan-3-one);
(58) Prostanozol (17-beta-hydroxy-5-alpha-androstano[3,2-c]pyrazole);
(59) Stanozolol (17-alpha-methyl-17-beta-hydroxy-[5-alpha]-androst-2-
eno[3,2-c]-pyrazole);
(60) Stenbolone (17-beta-hydroxy-2-methyl-[5-alpha]-androst-1-en-3-one);
(61) Testolactone (13-hydroxy-3-oxo-13,17-secoandrosta-1,4-dien-17-oic
acid lactone);
(62) Testosterone (17-beta-hydroxyandrost-4-en-3-one);
(63) Tetrahydrogestrinone (13-beta, 17-alpha-diethyl-17-beta-
hydroxygon-4,9,11-trien-3-one);
(64) Trenbolone (17-beta-hydroxyestr-4,9,11-trien-3-one);
(65) [3,2-c]-furazan-5 alpha-androstane-17 beta-ol;
(66) [3,2-c]pyrazole-androst-4-en-17 beta-ol;
(67) 17 alpha-methyl-androst-ene-3,17 beta-diol;
(68) 17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
(69) 17 alpha-methyl-androstan-3-hydroxyimine-17 beta-ol;
(70) 17 beta-hydroxy-androstano[2,3-d]isoxazole;
(71) 17 beta-hydroxy-androstano[3,2-c]isoxazole;
(72) 18a-homo-3-hydroxy-estra-2,5(10)-dien-17-one;
(73) 2 alpha, 3 alpha-epithio-17 alpha-methyl-5 alpha-androstan-17 beta-
ol;
(74) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3-one;
(75) 4-chloro-17 alpha-methyl-17 beta-hydroxy-androst-4-en-3,11-dione;
(76) 4-chloro-17 alpha-methyl-androst-4-ene-3 beta,17 beta-diol;
(77) 4-chloro-17 alpha-methyl-androsta-1,4-diene-3,17 beta-diol;
(78) 4-hydroxy-androst-4-ene-3,17-dione;
(79) 5 alpha-Androstan-3,6,17-trione;
(80) 6-bromo-androst-1,4-diene-3,17-dione;
LB877
2026
LB877
2026
-12-
(81) 6-bromo-androstan-3,17-dione;
(82) 6 alpha-methyl-androst-4-ene-3,17-dione;
(83) Delta 1-dihydrotestosterone;
(84) Estra-4,9,11-triene-3,17-dione; and
(85) Any salt, ester, or ether of a drug or substance described or listed
in this subdivision if the salt, ester, or ether promotes muscle growth.
(e) Hallucinogenic substances known as:
(1) Dronabinol, synthetic, in sesame oil and encapsulated in a soft
gelatin capsule in a drug product approved by the federal Food and Drug
Administration. Some other names for dronabinol are (6aR-trans)-6a,7,8,10a-
tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d)pyran-1-ol or (-)-delta-9-
(trans)-tetrahydrocannabinol.
Schedule IV
(a) Any material, compound, mixture, or preparation which contains any
quantity of the following substances, including their salts, isomers, and salts
of isomers whenever the existence of such salts, isomers, and salts of isomers
is possible within the specific chemical designation:
(1) Barbital;
(2) Chloral betaine;
(3) Chloral hydrate;
(4) Chlordiazepoxide, but not including librax (chlordiazepoxide
hydrochloride and clindinium bromide) or menrium (chlordiazepoxide and water
soluble esterified estrogens);
(5) Clonazepam;
(6) Clorazepate;
(7) Daridorexant;
(8) Diazepam;
(9) Ethchlorvynol;
(10) Ethinamate;
(11) Flurazepam;
(12) Mebutamate;
(13) Meprobamate;
(14) Methohexital;
(15) Methylphenobarbital;
(16) Oxazepam;
(17) Paraldehyde;
(18) Petrichloral;
(19) Phenobarbital;
(20) Prazepam;
(21) Alprazolam;
(22) Bromazepam;
(23) Camazepam;
(24) Clobazam;
(25) Clotiazepam;
(26) Cloxazolam;
(27) Delorazepam;
(28) Estazolam;
(29) Ethyl loflazepate;
(30) Fludiazepam;
(31) Flunitrazepam;
(32) Halazepam;
(33) Haloxazolam;
(34) Ketazolam;
(35) Loprazolam;
(36) Lorazepam;
(37) Lormetazepam;
(38) Medazepam;
(39) Nimetazepam;
(40) Nitrazepam;
(41) Nordiazepam;
(42) Oxazolam;
(43) Pinazepam;
(44) Temazepam;
(45) Tetrazepam;
(46) Triazolam;
(47) Midazolam;
(48) Quazepam;
(49) Zolpidem;
(50) Dichloralphenazone;
(51) Zaleplon;
(52) Zopiclone;
(53) Fospropofol;
(54) Alfaxalone;
(55) Suvorexant;
(56) Carisoprodol;
(57) Brexanolone; 3 alpha-hydroxy-5 alpha-pregnan-20-one;
(58) Lemborexant;
(59) Solriamfetol; 2-amino-3-phenylpropyl carbamate;
(60) Remimazolam;
(61) Serdexmethylphenidate; and
(62) Zuranolone (1-[2-[(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-
dimethyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carbonitrile).
LB877
2026
LB877
2026
-13-
(b) Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances having a stimulant effect on the central nervous system,
including their salts, isomers, whether optical, position, or geometric, and
salts of such isomers whenever the existence of such salts, isomers, and salts
of isomers is possible within the specific chemical designation:
(1) Diethylpropion;
(2) Phentermine;
(3) Pemoline, including organometallic complexes and chelates thereof;
(4) Mazindol;
(5) Pipradrol;
(6) SPA, ((-)-1-dimethylamino-1,2-diphenylethane);
(7) Cathine. Another name for cathine is ((+)-norpseudoephedrine);
(8) Fencamfamin;
(9) Fenproporex;
(10) Mefenorex;
(11) Modafinil; and
(12) Sibutramine.
(c) Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following narcotic drugs, or their salts or isomers calculated as the free
anhydrous base or alkaloid, in limited quantities as set forth below:
(1) Propoxyphene in manufactured dosage forms;
(2) Not more than one milligram of difenoxin and not less than twenty-five
micrograms of atropine sulfate per dosage unit; and
(3) 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts,
optical and geometric isomers, and salts of these isomers to include: Tramadol.
(d) Unless specifically excepted or unless listed in another schedule, any
material, compound, mixture, or preparation which contains any quantity of the
following substances, including their salts:
(1) Pentazocine; and
(2) Butorphanol (including its optical isomers).
(e) Any material, compound, mixture, or preparation which contains any
quantity of the following substance, including its salts, isomers, and salts of
such isomers, whenever the existence of such salts, isomers, and salts of
isomers is possible: Lorcaserin.
(f)(1) Unless specifically excepted or unless listed in another schedule,
any material, compound, mixture, or preparation which contains any quantity of
the following substance, including its salts, optical isomers, and salts of
such optical isomers: Ephedrine.
(2) The following drug products containing ephedrine, its salts, optical
isomers, and salts of such optical isomers, are excepted from subdivision (f)
(1) of Schedule IV if they (A) are stored behind a counter, in an area not
accessible to customers, or in a locked case so that a customer needs
assistance from an employee to access the drug product; (B) are sold by a
person, eighteen years of age or older, in the course of his or her employment
to a customer eighteen years of age or older with the following restrictions:
No customer shall be allowed to purchase, receive, or otherwise acquire more
than three and six-tenths grams of ephedrine base during a twenty-four-hour
period; no customer shall purchase, receive, or otherwise acquire more than
nine grams of ephedrine base during a thirty-day period; and the customer shall
display a valid driver's or operator's license, a Nebraska state identification
card, a military identification card, an alien registration card, or a passport
as proof of identification; (C) are labeled and marketed in a manner consistent
with the pertinent OTC Tentative Final or Final Monograph; (D) are manufactured
and distributed for legitimate medicinal use in a manner that reduces or
eliminates the likelihood of abuse; and (E) are not marketed, advertised, or
represented in any manner for the indication of stimulation, mental alertness,
euphoria, ecstasy, a buzz or high, heightened sexual performance, or increased
muscle mass:
(i) Primatene Tablets; and
(ii) Bronkaid Dual Action Caplets.
(g) Any pharmaceutical composition of crystalline polymorph psilocybin
approved by the federal Food and Drug Administration.
Schedule V
(a) Any compound, mixture, or preparation containing any of the following
limited quantities of narcotic drugs or salts calculated as the free anhydrous
base or alkaloid, which shall include one or more nonnarcotic active medicinal
ingredients in sufficient proportion to confer upon the compound, mixture, or
preparation valuable medicinal qualities other than those possessed by the
narcotic drug alone:
(1) Not more than two hundred milligrams of codeine per one hundred
milliliters or per one hundred grams;
(2) Not more than one hundred milligrams of dihydrocodeine per one hundred
milliliters or per one hundred grams;
(3) Not more than one hundred milligrams of ethylmorphine per one hundred
milliliters or per one hundred grams;
(4) Not more than two and five-tenths milligrams of diphenoxylate and not
less than twenty-five micrograms of atropine sulfate per dosage unit;
(5) Not more than one hundred milligrams of opium per one hundred
milliliters or per one hundred grams; and
(6) Not more than five-tenths milligram of difenoxin and not less than
twenty-five micrograms of atropine sulfate per dosage unit.
LB877
2026
LB877
2026
-14-
(b) Unless specifically exempted or excluded or unless listed in another
schedule, any material, compound, mixture, or preparation which contains any
quantity of the following substances having a stimulant effect on the central
nervous system, including its salts, isomers, and salts of isomers:
Pyrovalerone.
(c) Unless specifically exempted or excluded or unless listed in another
schedule, any material, compound, mixture, or preparation which contains any
quantity of the following substances having a depressant effect on the central
nervous system, including its salts, isomers, and salts of isomers:
(1) Ezogabine (N-(2-amino-4-(4-fluorobenzylamino)-phenyl)-carbamic acid
ethyl ester);
(2) Ganaxolone;
(3) Lacosamide ((R)-2-acetoamido-N-benzyl-3-methoxy-propionamide);
(4) Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid);
(5) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide)
(also referred to as BRV; UCB-34714; Briviact), including its salts;
(6) Cenobamate; and
(7) Lasmiditan.
Sec. 2. Original section 28-405, Revised Statutes Supplement, 2025, is
repealed.
LB877
2026
LB877
2026
-15-